



A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan

Tahara, Makoto ; Kiyota, Naomi ; Imai, Hiroo ; Takahashi, Shunji ; Nishiyama, Akihiro ; Tamura, Shingo ; Shimizu, Yasushi ; Kadowaki,...

(Citation)

Thyroid, 34(4):467-476

(Issue Date)

2024-04

(Resource Type)

journal article

(Version)

Version of Record

(Rights)

© Makoto Tahara et al., 2024; Published by Mary Ann Liebert, Inc.

This Open Access article is distributed under the terms of the Creative Commons License [CC-BY], which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

(URL)

<https://hdl.handle.net/20.500.14094/0100489410>






Figure S1. Patient flow diagram




Figure S2. Forest plot of the objective response rate for patients with DTC

^aBased on the assessment by independent review committee. CI, confidence interval; DTC, differentiated thyroid cancer; ECOG, Eastern Cooperative Oncology Group; N.A., not applicable; ORR, objective response rate; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitors.




Figure S3. Forest plot of the objective response rate for patients with ATC

^aBased on the assessment by independent review committee. ATC, anaplastic thyroid cancer; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; N.A., not applicable; ORR, objective response rate; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitors.